| Company Name: | Datascope Corporation | | Ticker Symbol: | DSCP | | | WWW Address: | www.datascope.com | | CEO: | Lawrence Saper | | No. of Employees: | 765 | | Common Issue Type: | CS | | Business Description: | A medical device company, which develops, manufactures and markets proprietary products for clinical health care markets in interventional cardiology, cardiovascular and vascular surgery and critical care.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 52.97 |  0.0 | - | - | 0 | 52.97 | 52.97 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 842.3 | 15.9 | 1.31 | 1.89 | 1.50 | 40.4 | 0.8 | 53.01 - 23.51 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 52.97 | $ | | PE Ratio - LTM | 40.4 | |
| Market Capitalisation | 842.3 | mil |
| Latest Shares Outstanding | 15.9 | mil |
| Earnings pS (EPS) | 1.89 | $ |
| Dividend pS (DPS) | 1.50 | ¢ |
| Dividend Yield | 0.8 | % |
| Dividend Payout Ratio | 79 | % |
| Revenue per Employee | 301,850 | $ |
| Effective Tax Rate | 34.1 | % |
| Float | 13.3 | mil |
| Float as % of Shares Outstanding | 83.6 | % |
| Foreign Sales | 132 | mil |
| Domestic Sales | 99 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 39.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 8.80 | % |
| Gross Profit Margin | 67.8 | % |
| EBITDA Margin | 20.0 | % |
| Pre-Tax Profit Margin | 14.5 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | 20.3 | % |
| Return on Equity (ROE) | 24.6 | % |
| Return on Capital Invested (ROCI) | 24.6 | % |
| Current Ratio | 6.5 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 18.33 | $ |
| Cash pS | 11.97 | $ |
| Book-Value pS | 25.02 | $ |
| Tangible Book-Value pS | 23.79 | $ |
| Cash Flow pS | 7.14 | $ |
| Free Cash Flow pS | -3.04 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.12 | |
| Price/Tangible Book Ratio | 2.23 | |
| Price/Cash Flow | 7.4 | |
| Price/Free Cash Flow | -17.4 | |
| P/E as % of Industry Group | 253.0 | % |
| P/E as % of Sector Segment | 157.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 0.40 |
| Current Dividend Yield | 0.8 |
| 5-Y Average Dividend Yield | 3.7 |
| Payout Ratio | 79.0 |
| 5-Y Average Payout Ratio | 105.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 100 | 1,780 | 0 |
| 4 Weeks | 53.01 | 52.46 | 52.70 | 0.5 | 108 | 1,704 | 25,562 |
| 13 Weeks | 53.01 | 48.00 | 51.22 | 3.4 | 117 | 1,879 | 107,090 |
| 26 Weeks | 53.01 | 23.51 | 48.07 | 10.2 | 173 | 1,689 | 204,356 |
| 52 Weeks | 53.01 | 23.51 | 35.88 | 47.6 | 238 | 1,260 | 311,211 |
| YTD | 53.01 | 52.07 | - | 1.4 | 111 | 1,777 | 37,324 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 52.89 | 52.75 | 52.20 | 50.09 | 48.13 | 1.31 | 0.11 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -4.57 | 23.5 | -11.64 |
| Income | 1.08 | 0.7 | 9.26 |
| Dividend | 39.09 | 50.8 | -7.62 |
| Capital Spending | 44.94 | NA | 73.06 |
| R&D | -4.84 | NA | -14.81 |
| Normalized Inc. | 8.11 | NA | 9.57 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -35.6 | -35.6 | -39.0 |
| Earnings % | -75.2 | -75.2 | 510.2 |
| EPS % | -76.3 | -76.3 | 65.8 |
| EPS $ | -0.58 | -0.58 | 0.75 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 53.04 |
| Current Ratio | 4.0 |
| Quick Ratio (Acid Test) | 3.4 |
| Liquidity Ratio (Cash) | 2.68 |
| Receivables Turnover | 3.1 |
| Average Collection Period | 116 |
| Working Capital/Equity | 68.7 |
| Working Capital pS | 17.59 |
| Cash-Flow pS | 7.86 |
| Free Cash-Flow pS | -0.92 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.73 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 22.8 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 6.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 1.16 |
| Tobin's Q Ratio | 1.60 |
| Current P/E Ratio - LTM | 40.40 |
| Enterprise Value (EV)/EBITDA | 12.92 |
| Enterprise Value (EV)/Free Cash Flow | -56.34 |
| Dividend Yield | 0.8 |
| Price/Tangible Book Ratio - LTM | 2.23 |
| Price/Book Ratio - LTM | 2.12 |
| Price/Cash Flow Ratio | 7.4 |
| Price/Free Cash Flow Ratio - LTM | -17.4 |
| Price/Sales Ratio | 3.00 |
| P/E Ratio (1 month ago) - LTM | 39.9 |
| P/E Ratio (26 weeks ago) - LTM | 25.0 |
| P/E Ratio (52 weeks ago) - LTM | 22.3 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 27.2 |
| Current P/E Ratio as % of 5-Y Average P/E | 149 |
| P/E as % of Industry Group | 253.0 |
| P/E as % of Sector Segment | 157.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 28.8 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 5.90 |
| Tangible Book Value pS - LTM | 23.79 |
| Book Value pS - LTM | 25.02 |
| Capital Invested pS | 25.49 |
| Cash pS - LTM | 11.97 |
| Cash Flow pS - LTM | 7.14 |
| Free Cash Flow pS - LTM | -3.04 |
| Earnings pS (EPS) | 1.89 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -6.33 |
| Free Cash Flow Margin 5YEAR AVG | -1.11 |
| Net Profit Margin | 46.2 |
| Net Profit Margin - 5YEAR AVRG. | 11.2 |
| Equity Productivity | 0.57 |
| Return on Equity (ROE) | 26.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.2 |
| Capital Invested Productivity | 0.57 |
| Return on Capital Invested (ROCI) | 26.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 12.2 |
| Assets Productivity | 0.50 |
| Return on Assets (ROA) | 20.3 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.4 |
| Gross Profit Margin | 67.8 |
| Gross Profit Margin - 5YEAR AVRG. | 64.1 |
| EBITDA Margin - LTM | 20.0 |
| EBIT Margin - LTM | 14.5 |
| Pre-Tax Profit Margin | 22.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 9.8 |
| Effective Tax Rate | 34.1 |
| Effective Tax Rate - 5YEAR AVRG. | 29.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 364 |
| Revenue per Employee | 301,850 |
| Net Income per Employee | 139,306 |
| Average Collection Period | 102 |
| Receivables Turnover | 3.1 |
| Day's Inventory Turnover Ratio | 262 |
| Inventory Turnover | 1.4 |
| Inventory/Sales | 13.4 |
| Accounts Payble/Sales | 7.34 |
| Assets/Revenue | 2.00 |
| Net Working Capital Turnover | 0.83 |
| Fixed Assets Turnover | 1.51 |
| Total Assets Turnover | 0.5 |
| Revenue per $ Cash | 10.45 |
| Revenue per $ Plant | 4.65 |
| Revenue per $ Common Equity | 0.57 |
| Revenue per $ Capital Invested | 0.57 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 40.1 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 39.2 |
| Research & Devlopment (R&D) as % of Revenue | 9.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 9.1 |
|
|  
|
| |
 |  |